Real-World Data Confirms Pepaxti Efficacy in Heavily Pretreated Multiple Myeloma Patients
核心洞察
Two real-world evidence studies from Spain and Italy demonstrate Pepaxti's effectiveness in heavily pretreated relapsed or refractory multiple myeloma (搜索) patients at the IMS Annual Meeting.
The Italian study reports a 47% overall response rate in patients who had received multiple prior therapies, including novel immunotherapies targeting BCMA (搜索) and GPRC5D (搜索).
Both studies confirm Pepaxti's favorable safety profile in real-world clinical settings, providing crucial evidence for treatment decisions outside controlled trial environments.
Oncopeptides AB has announced compelling real-world evidence demonstrating the efficacy and safety of Pepaxti (melflufen) in heavily pretreated multiple myeloma (搜索) patients, with data presented at the International Myeloma Society Annual Meeting in Toronto, Canada.
Italian Study Shows Strong Response Rates
The Italian study, conducted at centers in Bologna, reported an overall response rate of 47% in a heavily pretreated patient population with relapsed or refractory multiple myeloma (搜索). This real-world outcome confirms the efficacy previously demonstrated in the HORIZON clinical trial while maintaining a similar safety profile.
Notably, the study demonstrated efficacy in patients who had been treated with novel immunotherapies, underscoring Pepaxti's robust effectiveness in daily clinical practice. "Real-world data provide an essential complement to randomized clinical trials, especially when evaluating the effectiveness and tolerability of newer treatments in more complex, less selected patient populations," said Dott.ssa Katia Mancus, lead author for the Italian poster and hematologist at the Hematology Clinic in Bologna.
Spanish Data Addresses Critical Treatment Gap
The Spanish study from Valencia provides evidence of Pepaxti's efficacy in an even more heavily pretreated patient population, where the majority of patients had been exposed to either anti-BCMA (搜索) or anti-GPRC5D (搜索) immunotherapy. This data is particularly relevant for clinicians seeking guidance for treatment decisions in patients who have exhausted multiple therapeutic options.
Dr. Javier de la Rubia, lead author of the Spanish poster and hematologist at Hospital Universitario La Fe in Valencia, emphasized the clinical need: "There is a strong need for additional treatment options in later lines of therapy. Our study contributes to the understanding of how novel therapies are used in real-world clinical settings and the benefits they may offer to patients in Spain and beyond."
Safety Profile Confirmed in Clinical Practice
Both studies confirm Pepaxti's favorable tolerability profile in real-world settings, addressing a key consideration in multiple myeloma (搜索) treatment where safety challenges are common. The manageable side effect profile observed in these real-world studies aligns with the controlled trial experience.
Stefan Norin, Chief Medical Officer at Oncopeptides, commented on the significance of these findings: "These real-world data show that Pepaxti delivers compelling and meaningful outcomes for patients outside the controlled environment of clinical trials. The results confirm a positive clinical experience with Pepaxti, highlight its tolerability with manageable side effects, and provide highly relevant insights for physicians and payers in markets where treatment decisions increasingly rely on real-world evidence."
Growing Clinical Confidence
The acceptance of two real-world evidence case reports at a major international congress reflects increasing scientific interest and clinical engagement among European hematologists. Sofia Heigis, CEO of Oncopeptides, noted: "The acceptance of two RWE case reports at a major international congress is a testament to the scientific curiosity and engagement among European hematologists and speak to the positive clinical experience of Pepaxti."
For a medicine with limited awareness and use to date, these real-world data play a crucial role in building physician confidence and informing market access decisions. The studies follow a growing body of independent research reflecting clinical experiences across Europe, providing valuable evidence for countries where access is expanding and physicians seek real-world guidance for treatment decisions.